Le Lézard
Classified in: Health
Subject: ACC

MYM Closes Second Tranche of Non-Brokered Private Placement


VANCOUVER, British Columbia, July 17, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTCBB: MYMMF) ("MYM" or "The Company") announces it has closed the second tranche of its non-brokered private placement announced on July 5, 2019 of 2,528,174 units at a price of $0.324 for gross proceeds of $819,128. Included in this tranche is a drawdown on the Alumina Equity Agreement for $497,137. Finder's fees of $1,701 were paid on this tranche.

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.50 for a period of three years from the issue date. The warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the Company's share price on the Canadian Securities Exchange (or such other stock exchange the Company may be trading on) is equal or greater than $1.00 for a period of 10 consecutive trading days.

The offering was priced in the context of the market based on a price reservation made by the Company with the Canadian Securities Exchange. The private placement is subject to the approval of the CSE and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement to fund the strategic plan through 2020.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and CBD-rich hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD
Howard Steinberg, CEO
MYM Nutraceuticals Inc.
www.mym.ca 

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Billy Casselman
778-522-2261
investors@mym.ca

Keep up to date with MYM on our social media channels:
Twitter: @mymnutra
Facebook: @mymnutra
Instagram: @mymnutra

 

SOURCE MYM Nutraceuticals Inc.


These press releases may also interest you

at 00:10
Verseau Therapeutics, Inc. ("Verseau") launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua...

20 oct 2019
Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today...

20 oct 2019
Celltrion Healthcare today announced new data from a Phase 1 pivotal study to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 SC compared to the CT-P13 IV formulation in people with inflammatory bowel disease (IBD). Results...

20 oct 2019
Village Health Partners has a rich connection to the North Texas community, building on local partnerships for the past 11 years. The physicians at Village Health Partners collaborate with a team of local dietitians, counselors, pharmacists, and many...

20 oct 2019
Local, regional and national leaders of the United Church of Christ announced Oct. 20 that church donations have wiped out $5.3 million in medical debt for 5,888 South Side Chicago families. Families in three ZIP codes are now receiving letters...

20 oct 2019
LiveWell TMS, a new depression treatment facility, announced today it will host a grand opening event on Thursday, October 24, in celebration of its new location and in honor of National Depression Awareness Month. Co-founded by doctors Nina and Eric...



News published on 17 july 2019 at 07:23 and distributed by: